Key facts
- KAHR Bio’s last known valuation is $165.7M (Nov 2022).
- It has raised $183.3M; the latest was Later Stage VC ($32.0M) in Sep 2025.
- Notable investors include Korea Investment Partners, Innovation Authority, Peregrine Ventures, SPRIM Global Investments, Consensus Business Group — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for KAHR Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for KAHR Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KAHR Bio
Developer of a cancer drug intended to activate immune responses by converting cancer camouflage into beacons for the immune system to attack. The company specializes in the multifunctional immuno-recruitment protein technology to overcome the ability of cancers to evade recognition and elimination by the immune system, enabling doctors to help reduce patients' cancer cells.
- Sector
- Healthcare
- HQ
- Modi'in Makabim-Re'ut, Israel
- Founded
- 2005
- Employees
- 23
- Website
- kahrbio.base44.app/
- Ownership
- Privately Held (backing)
KAHR Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KAHR Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KAHR Bio in its N-PORT filings yet. We sweep new filings monthly.